Investor Presentaiton
Q1 2023 Financial Highlights (continued)
Total Revenue
($ in millions)
Short Distance
($ in millions)
MediMobility Organ
Transport
($ in millions)
+70%
$26.6
+111%
$45.3
+148%
$10.4
$12.7
$4.2
Jet/Other
($ in millions)
$26.8
$9.8
$8.1
Q1'22
Q1'23
Growth led by organic growth in
MediMobility Organ Transport and
inorganic growth in Short Distance
Q1'22
Q1'23
Growth driven by our acquisition
of Blade Europe, a continued
rebound in passenger travel in
Canada, and continued growth in
our Blade Airport service
•
Q1'22
Q1'23
Growth driven by the addition of
new transplant center customers,
continued growth with existing
customers, and strong end market
demand
•
Q1'22
Q1'23
Decline in revenue driven by a
normalization in jet charter volume
as well as lower average price per
charter trip
BLADE
23
23View entire presentation